Navigation Links
Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
Date:3/15/2010

medically appropriate dose or for whom these drugs are contraindicated.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase®, from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

FORWARD-LOOKING LANGUAGE

All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believ
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
2. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
3. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
4. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
7. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Savient Provides Update on Pegloticase BLA
9. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  AbbVie (NYSE: ... several clinical studies evaluating potential new medicines in ... the upcoming 2014 European Society of Medical Oncology ... Madrid, Spain . Data being presented include ... safety and efficacy of veliparib (ABT-888), a poly ...
(Date:9/22/2014)... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today ... overview and update at the NewsMakers in the Biotech ... a.m. Eastern Time (8:30 a.m. Pacific Time), at the ... . A live audio webcast of ... section of Arena,s website at www.arenapharm.com . A ...
(Date:9/22/2014)... , September 22, 2014 ... "Cell Line Development Market by Product (Equipment, Media and ... Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, ... 2019", published by MarketsandMarkets, analyzes and studies the ... Browse 114 market data tables and ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
... Dec. 7 Access Pharmaceuticals, Inc.,(OTC Bulletin ... demonstrated the,ability, using the company,s proprietary Cobalamin(TM) ... animal model of diabetes, through,its oral insulin ... based upon the body,s natural absorption of ...
... DENVER, Dec. 6 Some 5,000 COPD patients ... Antitrypsin Deficiency (Alpha-1) in,a study marking a major ... Association for Respiratory Care (AARC)., The principal ... the,Division of Pulmonary Medicine, National Jewish Medical and ...
Cached Medicine Technology:Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin 2Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin 3Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 2Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 3
(Date:9/22/2014)... York (PRWEB) September 22, 2014 ... Boston Scientific Corp. continue to move forward in ... District Court, Southern District of West Virginia, Bernstein ... new Docket Control Order was issued by the ... of matters pertaining to the upcoming trial for ...
(Date:9/22/2014)... percent of patients undergoing breast cancer surgery require additional ... cancerous tissue in the initial operation. However, researchers at ... tool they developed that will help surgeons better distinguish ... chances for repeat operations. , The ... 2014 in the Proceedings of the National Academy ...
(Date:9/22/2014)... PITTSBURGH, PA (PRWEB) September 22, 2014 ... caring for patients to the problem of side-sleeping. "My ... my side, so I designed a solution to this ... fall asleep comfortably than to have your arm 'fall ... sleep on his or her side more comfortably. It ...
(Date:9/22/2014)... The R&D of cancer vaccines has seen ... important data received from clinical research studies have confirmed ... challenge to the development of such vaccines is the ... how a human’s immune system works. The administration of ... owing to known factors with genetics possibly playing a ...
(Date:9/22/2014)... Barbara Bronson Gray ... -- It,s something every pregnant woman wonders: What can I ... suggests that taking iron supplements as prescribed may play a ... autism spectrum disorder (ASD). The researchers found that mothers ... taken iron supplements before and during pregnancy than those whose ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 4Health News:The fine line between breast cancer and normal tissues 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3
... interested in pursuing careers in health, science or mathematics-related ... Carolina Student Loan Program for Health, Science and Mathematics ... information site, CFNC.org. , ... for Health, Science and Mathematics (HSM) was established in ...
... Robert W. Woodruff Foundation has pledged $3 million toward ... of Dentistry building. , "This is great news for ... helps demonstrate to other foundations and corporations, and to ... contingent upon groundbreaking for the new building during the ...
... MILWAUKEE, Dec. 15 Aurora Health Care announced ... largest radiology,practices in southeastern Wisconsin, have chosen to join Aurora ... 33 Great Lakes radiologists practice chiefly at Aurora hospitals and,clinics. ... physicians who every day contribute to the quality,of the care ...
... one small chocolate truffle can induce cravings for more ... high-end status products, according to a new study in ... a study that examined goals and behavior in consumers, ... (University of Florida) found that study participants who consumed ...
... transparency , , PITTSBURGH, ... its members with online physician quality information in an effort ... , , "Today, more people ... obtain the best care at the best price," said Dr. ...
... the efficacy of The Pink Patch for weight control ... kg) in 4 weeks. The Pink Patch is a ... weight loss goals. Dr. Hudson stated in her ... any dietary or activity changes, The Pink Patch, can ...
Cached Medicine News:Health News:North Carolina Student Loan Program for Health, Science and Mathematics Application Will Be Available December 20, 2008 2Health News:Woodruff Foundation pledges $3 million toward MCG dental building 2Health News:Great Lakes Radiologists to Join Aurora Medical Group 2Health News:Slippery slope: 1 tiny truffle can trigger desire for more treats 2Health News:Highmark Blue Cross Blue Shield Provides Online Physician Quality Information to Members 2Health News:Double Blind Study Proves The Pink Patch Works for Weight Loss 2Health News:Double Blind Study Proves The Pink Patch Works for Weight Loss 3